Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy

Next Previous
Trial Profile

ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Batoclimab (Primary)
  • Indications Graves ophthalmopathy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASCEND-GO 2
  • Sponsors Immunovant

Most Recent Events

  • 28 Mar 2022 According to an Immunovant media release, company will host a virtual R&D event to discuss and present data from this study.
  • 14 Feb 2022 According to an Immunovant media release, the company plans to re-initiate its programs in thyroid eye disease in 2022.
  • 01 Jun 2021 Status changed from suspended to discontinued, according to Ligand Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top